These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
Pubmed for Handhelds
PUBMED FOR HANDHELDS
Journal Abstract Search
128 related items for PubMed ID: 38131519
21. The outcomes of indocyanine green angiography monitored immunotherapy in Vogt-Koyanagi-Harada disease. Chee SP, Jap A. Br J Ophthalmol; 2013 Feb; 97(2):130-3. PubMed ID: 23212203 [Abstract] [Full Text] [Related]
22. Predictive factors and adalimumab efficacy in managing chronic recurrence Vogt-Koyanagi-Harada disease. Feng H, Chen W, Yang J, Kong H, Li H, He Y, Wang H. BMC Ophthalmol; 2024 Jun 07; 24(1):238. PubMed ID: 38849758 [Abstract] [Full Text] [Related]
23. Choroidal observations in Vogt-Koyanagi-Harada disease using high-penetration optical coherence tomography. Nakai K, Gomi F, Ikuno Y, Yasuno Y, Nouchi T, Ohguro N, Nishida K. Graefes Arch Clin Exp Ophthalmol; 2012 Jul 07; 250(7):1089-95. PubMed ID: 22240936 [Abstract] [Full Text] [Related]
24. The outcomes of mycophenolate mofetil therapy combined with systemic corticosteroids in acute uveitis associated with Vogt-Koyanagi-Harada disease. Abu El-Asrar AM, Hemachandran S, Al-Mezaine HS, Kangave D, Al-Muammar AM. Acta Ophthalmol; 2012 Dec 07; 90(8):e603-8. PubMed ID: 22971163 [Abstract] [Full Text] [Related]
25. Retinal fluorescein and indocyanine green angiography and optical coherence tomography in successive stages of Vogt-Koyanagi-Harada disease. Fardeau C, Tran TH, Gharbi B, Cassoux N, Bodaghi B, LeHoang P. Int Ophthalmol; 2007 Dec 07; 27(2-3):163-72. PubMed ID: 17273903 [Abstract] [Full Text] [Related]
26. Vogt-Koyanagi-Harada Disease Managed With Immunomodulatory Therapy Within 3 Months of Disease Onset. Ei Ei Lin Oo, Chee SP, Wong KKY, Hla Myint Htoon. Am J Ophthalmol; 2020 Dec 07; 220():37-44. PubMed ID: 32738228 [Abstract] [Full Text] [Related]
27. [Fundus fluorescein and indocyanine green angiographic study of Behcet's disease and Vogt-Koyanagi-Harada syndrome]. Chen L, Yang P, Wen F, Zhou H, Huang X. Zhonghua Yan Ke Za Zhi; 2002 Apr 07; 38(4):210-2. PubMed ID: 12133388 [Abstract] [Full Text] [Related]
28. The effect on choroidal changes of the route of systemic corticosteroids in acute Vogt-Koyanagi-Harada disease. Park UC, Cho IH, Lee EK, Yu HG. Graefes Arch Clin Exp Ophthalmol; 2017 Jun 07; 255(6):1203-1211. PubMed ID: 28382438 [Abstract] [Full Text] [Related]
29. Prognostic factors for clinical outcomes in patients with Vogt-Koyanagi-Harada disease treated with high-dose corticosteroids. Abu El-Asrar AM, Al Tamimi M, Hemachandran S, Al-Mezaine HS, Al-Muammar A, Kangave D. Acta Ophthalmol; 2013 Sep 07; 91(6):e486-93. PubMed ID: 23575246 [Abstract] [Full Text] [Related]
30. Choroidal folds in Vogt-Koyanagi-Harada disease. Wu W, Wen F, Huang S, Luo G, Wu D. Am J Ophthalmol; 2007 May 07; 143(5):900-901. PubMed ID: 17452188 [Abstract] [Full Text] [Related]
31. Depigmented atrophic lesions in sunset glow fundi of Vogt-Koyanagi-Harada disease. Inomata H, Rao NA. Am J Ophthalmol; 2001 May 07; 131(5):607-14. PubMed ID: 11336935 [Abstract] [Full Text] [Related]
32. Suboptimal therapy controls clinically apparent disease but not subclinical progression of Vogt-Koyanagi-Harada disease. Kawaguchi T, Horie S, Bouchenaki N, Ohno-Matsui K, Mochizuki M, Herbort CP. Int Ophthalmol; 2010 Feb 07; 30(1):41-50. PubMed ID: 19151926 [Abstract] [Full Text] [Related]
33. Incidence, Risk Factors and Surgical Outcomes of Cataract among Patients with Vogt-Koyanagi-Harada Disease. AlBloushi AF, Alfawaz AM, AlZaid A, Alsalamah AK, Gikandi PW, Abu El-Asrar AM. Ocul Immunol Inflamm; 2021 Jan 02; 29(1):128-136. PubMed ID: 31638886 [Abstract] [Full Text] [Related]
34. Clinical characteristics of Vogt-Koyanagi-Harada syndrome in Chinese patients. Yang P, Ren Y, Li B, Fang W, Meng Q, Kijlstra A. Ophthalmology; 2007 Mar 02; 114(3):606-14. PubMed ID: 17123618 [Abstract] [Full Text] [Related]